CTO Crossing Device Patents: Top Companies & Filing Trends 2026
Chronic Total Occlusion Crossing Device Patents
33.8% concentration at the top. The five leading assignees hold 329 of 972 records in scope, but the next tier drops off fast — a long tail of single- and few-filing entrants fills the rest of the ranking. Annual filings rose from 30 in 2017 to a peak of 85 in 2019, then continued at elevated levels through 2021-2024, when filings grew from 43 to 84 — a 95% increase over that three-year span. 2025 and 2026 figures (down to 7 in the partial latest year) understate real activity because publication typically lags filing by around 18 months.
- 1RETROVASCULAR INC90
- 2SHOCKWAVE MEDICAL INC78
- 3ASAHI INTECC CO LTD69
- 4MEDINOL LTD50
- 5BOSTON SCIENTIFIC SCIMED INC42
See the full chronic total occlusion crossing devices analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about CTO crossing device patents
Who holds the most patents on chronic total occlusion crossing devices?
The patent ranking covers 100 assignees across 972 records, and it is concentrated at the top: the leading assignee holds 90 records, well ahead of fifth place at 42 and tenth place at 26. Together the top five hold 329 records, or 33.8% of the 972 in scope, and the top ten hold 483, or 49.7%. Below that the field thins into a long tail of companies with only a handful of filings each, so due diligence should weight the leaders heavily but not assume the rest of the field is empty.
What technology areas dominate CTO crossing device patent filings?
Diagnosis-and-surgery devices (IPC class A61B) appear in 71.0% of the 972 records and body-fluid delivery devices (A61M) in 57.8%, making these the two anchor classes for the field. Implant and prosthesis claims (A61F) follow at 16.2%, while sterilisation, medicinal-preparation, imaging and informatics classes each cover single-digit shares. That split shows the field is still primarily about physical crossing mechanics rather than software-assisted navigation or diagnostics.
Is patent filing activity for CTO crossing devices growing or slowing?
Filings grew substantially in the most recently complete filing years, rising 95% from 43 in 2021 to 84 in 2024. An earlier peak of 85 filings occurred in 2019, so growth has been non-linear rather than a single steady climb. Counts for 2025 and 2026 appear lower, but that reflects the roughly 18-month lag between filing and publication rather than an actual slowdown, so those recent years should not be read as a decline.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Chronic Total Occlusion Crossing Devices covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.